Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Moro-Sibilot, Denis; Smit, Egbert F.; Castro, Javier de; Leśniewski-Kmak, Krzysztof; Aerts, Joachim; Villatoro, R.; Kraaij, Kees; Nacerddine, Karim; D’yachkova, Yulia; Smith, Karen; Girvan, Allicia C.; Visseren‐Grul, Carla; Schnabel, Philipp A.

doi:10.1016/j.lungcan.2015.11.011

Cited by 64 publications

(52 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, it is a non-invasive imaging modality, induces no pain, is low-cost, has an extensive range and high-resolution (33). Although ultrasound diagnosis is beneficial for use in the clinic, it has been previously reported that numerous factors, including performance status, comorbidity, sex and age, affect the diagnosis of patients with early-stage lung cancer (8). However, all of these factors cannot be modified prior to clinical application.…”

Section: Discussionmentioning

confidence: 99%

“…A previous study (8) has indicated that large cell carcinoma accounts for <10% in patients with lung cancer. Diagnosis of large cell carcinoma in the chest wall is challenging due to poor imaging quality of conventional ultrasound and the fact that features remain nonspecific in diagnostics.…”

Section: Contrast-enhanced Ultrasound: Large Cell Carcinomamentioning

confidence: 98%

“…Previous studies have demonstrated that NSCLC has the highest incidence rate among all cancer types worldwide (5,6). It is the most common type of lung cancer accounting for >80% of all lung cancer cases and includes squamous cell carcinoma, large cell carcinoma and adenocarcinoma (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Han

Jing

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) initiates in the non-small cells of the lung and is one of the most common types of human cancer. It is known for its rapid growth, easy migration, invasion and reoccurrence, and has the highest incidence rate of all types of cancer. Early detection of NSCLC is difficult to achieve and this is the primary reason for low survival rates in NSCLC. Contrast-enhanced ultrasound is the most common application for evaluating patients diagnosed with NSCLC. In the present study, a contrast-enhanced ultrasound combined with nanoparticles was performed with the aim of identifying patients with NSCLC at an early stage. The present study evaluated the effectiveness of administering a nanoparticle contrast agent through respiration in combination with enhanced ultrasound at improving image quality compared with traditional ultrasound. This maybe a novel method of detecting early-stage tumors in patients. There are numerous benefits to conducting diagnoses of NSCLC using contrast-enhanced ultrasound. It is a non-invasive imaging modality, induces little pain, has a low cost, an extensive range and produces high-resolution images. This means that it is safer and more beneficial to use in patients with NSCLC than conventional imaging examinations, including X-ray and bronchoscopy. Furthermore, the nanoscale microbubble contrast agent containing liposome-encapsulated epidermal growth factor receptor was inhaled by nebulization, which may lead to an enhanced ultrasound image. The sensitivity of contrast-enhanced ultrasound was investigated in mice with early stage NSCLC. The results indicated that ultrasound administrated with nanoscale microbubble enhanced sensitivity and improved image quality compared with simple ultrasound. Furthermore, enhanced ultrasound resulted in a reliable and sensitive assessment of tumor mass in early-stage tumors. Altogether, contrast-enhanced ultrasound facilitated the efficient detection of NSCLC in patients in situ at an early stage. This protocol improved the understanding of the pathophysiology of NSCLC and may be applied in the detection of early-stage tumors in patients suspected of having cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Contrast-enhanced Ultrasound: Large Cell Carcinomamentioning

confidence: 98%

See 1 more Smart Citation

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Han

Jing

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…It should be emphasized, however, that these studies have some important limitations, mainly because of the low number of patients enrolled and the selection of patients with good prognosis, therefore the transferability of the results can be questionable. Recently, a post-hoc analysis of a large prospective observational European study on 1,564 patients with newly diagnosed advanced NSCLC receiving a platinum-based regimen as first-line treatment, showed that in the subset of 263 patients with BMs the median OS was 7.2 months, ranging from 5.6 months for those treated with cisplatin plus gemcitabine up to 9.3 months for those treated with platinum plus pemetrexed (53). Interestingly, only 34% of patients had previously received cranial radiotherapy.…”

Section: Clinical Activity Of Chemotherapy Against Bms From Nsclcmentioning

confidence: 99%

State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer

Inno¹,

Noia²,

D’Argento³

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Chemotherapy is the mainstay of treatment of advanced non-small cell lung cancer (NSCLC) without molecular drivers. Despite a low penetration of central nervous system (CNS), chemotherapy drugs demonstrated encouraging activity against CNS metastases from NSCLC. Based on the available data, chemotherapy should be considered as an important part of the multidisciplinary treatment of CNS metastases. Particularly, platinum-based regimens represent the most active combinations and pemetrexed is associated with a meaningful clinical benefit for patients with non-squamous histology. How to integrate chemotherapy and radiotherapy for newly diagnosed brain metastases (BMs) is still debated. Although flawed by some limitations, the available evidence suggests a role for upfront chemotherapy for the treatment of NSCLC patients with synchronous, asymptomatic BMs, thus allowing a delay of radiotherapy. Despite the introduction of modern and more effective chemotherapy, however, the prognosis of NSCLC patients with CNS metastases remains poor, especially for those with progressive BMs or leptomeningeal carcinomatosis (LC).

show abstract

“…The types of NSCLC include adenocarcinoma, large cell carcinoma and squamous cell carcinoma, which together account for ~80% of all lung cancer cases (6,7). Despite advancements in the therapeutic regimens for lung cancer, the survival rate of patients with NSCLC remains poor (8)(9)(10). This is due to NSCLC typically being diagnosed at an advanced stage (11,12).…”

Section: Introductionmentioning

confidence: 99%

Contrast‑enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early‑phase non‑small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) is a major cause of morbidity and mortality, and patients with NSCLC are frequently diagnosed at an advanced stage. This is primarily due to a lack of advanced and sensitive protocols for the detection of early stage NSCLC. Therefore, methods for the accurate diagnosis of early stage NSCLC are urgently required to improve survival rates. The present study investigated the use of contrast-enhanced computerized tomography (CECT) combined with a targeted nanoparticle contrast agent (TNCA) to diagnose early-stage NSCLC in a mice xenograft model. The TNCA used was lenvatinib, a multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, proto-oncogene tyrosine-protein kinase receptor Ret and mast/stem cell growth factor receptor Kit. Xenograft NSCLC mice were established and used to analyze the efficacy of CECT-TNCA compared with CT scanning alone. The TNCA was inhaled with the use of an atomizer. The results demonstrated that CECT-TNCA improved the sensitivity of the diagnosis of early stage NSCLC. In addition, imaging using the TNCA enabled the visualization of nodules in the lung in mice with early stage NSCLC. In addition, lung nodule signal enhancement was increased in CECT-TNCA compared with CT, suggesting a high accurate accumulation of the TNCA in tumor nodules. Mice diagnosed with early stage NSCLC exhibited a higher eradication rate of NSCLC after treatment with cisplatin compared with mice with advanced stage NSCLC. These data indicate that the sensitivity and accuracy of CT imaging for the diagnosis of early stage NSCLC was improved through combination with the liposome-encapsulated TNCA.

show abstract

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Cited by 64 publications

References 11 publications

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer

Contrast‑enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early‑phase non‑small cell lung cancer

Contact Info

Product

Resources

About